Tonix Pharmaceuticals Holding Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Für Tonix Pharmaceuticals Holding wird ein Gewinn- und Umsatzwachstum von 27.2% bzw. 42.7% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 50.9% pro Jahr steigen soll.

Wichtige Informationen

27.2%

Wachstumsrate der Gewinne

50.87%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	25.1%
Wachstumsrate der Einnahmen	42.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	06 Jul 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Seeking Alpha • Jun 29

Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating

Summary Tonix Pharmaceuticals remains rated Hold as Tonmya's commercial launch underwhelms, with Q1 2026 net product revenue at $3.7m, arguably below expectations. TNXP's cash runway is limited, with $185.5m on hand and quarterly net losses exceeding $40m, raising future funding concerns. Competitive pressure and uncertain pipeline prospects, including MDD and Lyme disease candidates, temper confidence in TNXP's ability to drive meaningful upside. I maintain a Hold, seeing limited near-term catalysts but potential upside if Tonmya sales accelerate or pipeline assets deliver unexpected positive data. Read the full article on Seeking Alpha

Analyseartikel • Dec 01

Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analyseartikel • Aug 14

Here's Why We're Not Too Worried About Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Situation

NasdaqCM:TNXP 1 Year Share Price vs Fair Value Explore Tonix Pharmaceuticals Holding's Fair Values from the Community...

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:TNXP - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2028	163	-85	-170	-137	4
12/31/2027	79	-152	-205	-152	4
12/31/2026	34	-170	-200	-144	4
3/31/2026	18	-147	-131	-126	N/A
12/31/2025	13	-124	-103	-100	N/A
9/30/2025	10	-99	-76	-75	N/A
6/30/2025	10	-81	-65	-65	N/A
3/31/2025	10	-132	-60	-60	N/A
12/31/2024	10	-130	-61	-61	N/A
9/30/2024	11	-135	-69	-69	N/A
6/30/2024	12	-149	-76	-73	N/A
3/31/2024	10	-99	-91	-87	N/A
12/31/2023	8	-117	-110	-102	N/A
9/30/2023	4	-123	-114	-102	N/A
6/30/2023	N/A	-124	-121	-102	N/A
3/31/2023	N/A	-123	-132	-100	N/A
12/31/2022	N/A	-117	-146	-98	N/A
9/30/2022	N/A	-112	-167	-98	N/A
6/30/2022	N/A	-102	-156	-88	N/A
3/31/2022	N/A	-98	-141	-86	N/A
12/31/2021	N/A	-92	-111	-76	N/A
9/30/2021	N/A	-80	-81	-67	N/A
6/30/2021	N/A	-73	-80	-69	N/A
3/31/2021	N/A	-64	-69	-60	N/A
12/31/2020	N/A	-52	-57	-49	N/A
9/30/2020	N/A	-46	-45	-41	N/A
6/30/2020	N/A	-42	-33	-33	N/A
3/31/2020	N/A	-34	-27	-27	N/A
12/31/2019	N/A	-31	N/A	-27	N/A
9/30/2019	N/A	-31	N/A	-27	N/A
6/30/2019	N/A	-28	N/A	-25	N/A
3/31/2019	N/A	-29	N/A	-26	N/A
12/31/2018	N/A	-29	N/A	-24	N/A
9/30/2018	N/A	-24	N/A	-22	N/A
6/30/2018	N/A	-24	N/A	-22	N/A
3/31/2018	N/A	-23	N/A	-21	N/A
12/31/2017	N/A	-21	N/A	-19	N/A
9/30/2017	N/A	-23	N/A	-20	N/A
6/30/2017	N/A	-25	N/A	-23	N/A
3/31/2017	N/A	-30	N/A	-27	N/A
12/31/2016	N/A	-39	N/A	-37	N/A
9/30/2016	N/A	-45	N/A	-44	N/A
6/30/2016	N/A	-50	N/A	-48	N/A
3/31/2016	N/A	-52	N/A	-49	N/A
12/31/2015	N/A	-48	N/A	-43	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: TNXP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: TNXP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: TNXP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: TNXPDie Einnahmen des Unternehmens (42.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (12.7% pro Jahr).

Hohe Wachstumseinnahmen: TNXPDie Einnahmen des Unternehmens (42.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von TNXP in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/07/06 07:00
Aktienkurs zum Tagesende	2026/07/06 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Tonix Pharmaceuticals Holding Corp. wird von 11 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
James Molloy	Alliance Global Partners
Chiara Russo	Brean Capital Historical (Janney Montgomery)
David Buck	B. Riley Securities, Inc.

Tonix Pharmaceuticals Holding Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 58%

Forecast to breakeven in 2028

Consensus revenue estimates increase by 21%

Forecast to breakeven in 2028

Price target decreased by 20% to US$54.33

Consensus EPS estimates upgraded to US$13.03 loss

Recent updates

Tonix Pharmaceuticals Enrolls First Patient in Phase 2 Study for Major Depressive Disorder

Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder

Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating

Co-Founder recently bought US$59k worth of stock

Tonix Pharmaceuticals Holding Corp. Announces Publication Of Phase 1 Clinical Data Of TNX-1500 Fc-Modified Anti-CD40L Monoclonal Antibody

Tonix Pharmaceuticals Presents Real-World Claims Analysis And Launches TONMYA For Fibromyalgia Treatment

Consensus revenue estimates decrease by 58%

New minor risk - Share price stability

New minor risk - Profitability

Forecast to breakeven in 2028

Consensus revenue estimates increase by 21%

New minor risk - Profitability

Tonix Pharmaceuticals Holding Corp. Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of Tnx-4800

Co-Founder recently bought US$63k worth of stock

New minor risk - Share price stability

Tonix Pharmaceuticals Holding Corp Presents Phase 1 Data And Outlines Planned Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease

Tonix Pharmaceuticals Holding Corp Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900

Forecast to breakeven in 2028

Tonix Pharmaceuticals Holding Corp., Annual General Meeting, May 07, 2026

Co-Founder recently bought US$223k worth of stock

Price target decreased by 20% to US$54.33

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Tonix Pharmaceuticals Presents Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Tonix Pharmaceuticals Holding Corp Announces Publication of Clinical Pharmacokinetic Studies of TONMYA and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

New minor risk - Share price stability

Tonix Pharmaceuticals Holding Corp. Presents Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) At the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals Holding Corp. Announces Program Updates on Tnx-4800 Product Candidate for Protection Against Lyme Disease

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $19.999998 million.

Tonix Pharmaceuticals Holding Corp. Appoints Irina Ishak as General Counsel, Effective December 8, 2025

Consensus EPS estimates upgraded to US$13.03 loss

Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?

Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA (Cybobenzaprine HCl Sublingual Tablets) as A First-In-Class Fibromyalgia Treatment

Third quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat

Tonix Pharmaceuticals Holding Corp. Presents Data on Tonmya at the 2025 American College of Rheumatology Convergence

Tonix Pharmaceuticals Holding Corp. Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Tonix Pharmaceuticals Holding Corp. Presents Data on TNX-801 Mpox Vaccine at World Vaccine Congress-Europe 2025

Tonix Pharmaceuticals Holding Corp. Appoints Ganesh Kamath as Head of Market Access, Effective September 29, 2025

Tonix Pharmaceuticals Holding Corp. Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of Tnx-2900 (Intranasal Potentiated Oxytocin) in 2026

Tonix Pharmaceuticals Holding Corp. Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Holding Corp. Presents Clinical Data on Tonmya for the Treatment of Fibromyalgia at PAINWEEK 2025

Tonix Pharmaceuticals Holding Corp. Announces FDA Approval of Tonmya (cyclobenzaprine HCl Sublingual Tablets) for the Treatment of Fibromyalgia

Here's Why We're Not Too Worried About Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Situation

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

New major risk - Share price stability

Tonix Pharmaceuticals Holding Corp. to Report Q2, 2025 Results on Aug 11, 2025

Tonix Pharmaceuticals Holding Corp. Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

Tonix Pharmaceuticals Holding Corp. Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

High number of new directors

Tonix Pharmaceuticals Holding Corp. Appoints James ‘Jim’ Hunter to Board of Directors, Effective June 12, 2025

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $150 million.

Consensus revenue estimates increase by 15%

Tonix Pharmaceuticals Holding Corp. Announces First Patient Dosed in Phase 2 Oasis Study of TNX-102 SL for Reduction of Acute Stress Response

Consensus EPS estimates upgraded to US$12.40 loss, revenue downgraded

Co-Founder recently bought US$86k worth of stock

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 88% to US$60.00

Tonix Pharmaceuticals Holding Corp. Presents Data on Potential Mpox Vaccine TNX-801 at World Vaccine Washington 2025

Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia At the American Academy of Pain Medicine 2025 Annual Meeting

Tonix Pharmaceuticals Holding Corp. Launches Tonix One™, A Fully-Integrated Digital Platform Designed to Help Patients Better Understanding and Manage Their Migraine Condition

Tonix Pharmaceuticals Holding Corp. Announces U.S. Food and Drug Administration to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate

Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of Tnx-102 Sl Treatment Effects on Fibromyalgia At 7Th International Congress on Cont Cont Cont Cont Cont Cont Contconties in Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Provides Earnings Guidance for the Full Year Ended December 31, 2024

Tonix Pharmaceuticals Holding Corp. Announces Positive Topline Results from Phase 1 Trial for TNX-1500, Next Generation Anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases

Tonix Pharmaceuticals Holding Corp. Announces Promotion of Siobhan Fogarty to Chief Technical Officer

Tonix Pharmaceuticals Holding Corp. Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Announces Fda Acceptance of the New Drug Application (Nda) for Tnx-102 Sl for Fibromyalgia